Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up

European Journal of Preventive Cardiology

Volumn 11, Issue 2, 2004, Pages 135-143

  Fisman, Enrique Z ^a   Motro, Michael ^a   Tenenbaum, Alexander ^a   Leor, Jonathan ^a   Boyko, Valentina ^b   Mandelzweig, Lori ^b   Adler, Yehuda ^a   Behar, Solomon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

cancer; coronary artery disease; hypoglycaemia; mortality

Indexed keywords

BEZAFIBRATE; GLUCOSE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE;

AGED; BLOOD GLUCOSE; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIA; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 2342637705     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000124326.85096.ec     Document Type: Article

References (35)

1. Clutter WE, Cryer PE. Hypoglycemia. In: Stein JH (editor): Internal medicine. Boston: Little Brown & Co; 1990, pp. 2267–2272.
2. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997; 20: 163–169.
3. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: The San Antonio Heart Study. Diabetes Care 1998; 21: 1167–1172.
4. Fisman EZ, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J 2001; 141: 485–490.
5. Malouf R, Brust JC. Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol 1985; 17: 421–430.
6. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation 2000; 101: 2047–2052.
7. Herrmann BL, Saller B, Kiess W, Morgenroth K, Drochner K, Schroder T, et al. Primary malignant fibrous histiocytoma of the lung: IGF-II producing tumor induces fasting hypoglycemia. Exp Clin Endocrinol Diabetes 2000; 108: 515–518.
8. Pourmotabbed G, Kitabchi AE. Hypoglycemia. Obstet Gynecol Clin North Am 2001; 28: 383–400.
9. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kapinski E, Graff E, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993; 71: 909–915.
10. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183–1197.
11. Tenenbaum A, Motro M, Fisman EZ, Boyko V, Mandelzweig L, Reicher-Reiss H, et al. Clinical impact of borderline and undiagnosed diabetes mellitus in patients with coronary artery disease. Am J Cardiol 2000; 86: 1363–1366.
12. International Classification of Diseases. Clinical modification. 9th Revision, vol. I. Ann Arbor: Edwards Bros.; 1981.
13. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary artery disease patients. Arterioscler Thromb Vasc Biol 1996; 16: 351–356.
14. SAS Institute Inc. SAS/STAT. User's guide. Version 6, 4th edn, vol. 2. Cary, NC: SAS Institute Inc.; 1987.
15. Yaari S, Goldbourt U. A SAS program for evaluating person-years of risk on cohort studies. Comp Biol Med 1989; 19: 353–359.
16. SAS/STAT software. Changes and enhancements. Release 6.07. SAS technical report P-229. Cary, NC: SAS Institute Inc., p. 620, 1992.
17. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15–36.
18. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996; 46: 5–27.
19. Service FJ. Hypoglycemic disorders. N Engl J Med 1995; 332: 1144–1152.
20. Aronen HJ, Pardo FS, Kennedy DN, Belliveau JW, Packard SD, Hsu DW, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: 2189–2200.
21. Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 1997; 14: 648–654.
22. Saunders FM, Llewellyn T. Silent myocardial infarction during hypoglycaemic coma. J Accid Emerg Med 1996; 13: 357–358.
23. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus. The Verona Diabetes Study. Circulation 1997; 96: 1750–1754.
24. Tenenbaum A, Grossman E, Fisman EZ, Adler Y, Boyko V, Jonas M, et al. Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up. J Human Hypertens 2001; 15: 373–379.
25. Tenenbaum A, Motro M, Jonas M, Fisman EZ, Grossman E, Boyko V, et al. Is long-term diuretic therapy associated with increased risk of colon cancer? Am J Med 2001; 110: 143–145.
26. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999; 83: 1090–1093.
27. Rieder J, Marth C, Totzke G, Smolny M, Seibel M, Hoffmann G. Different patterns of inducible nitric oxide synthase gene expression in ovarian carcinoma cell lines. Anticancer Res 2000; 20: 3251–3258.
28. Murakami A, Kawabata K, Koshiba T, Gao G, Nakamura Y, Koshimizu K, et al. Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant, JB6 mouse epidermal cells cocultured with interferon-stimulated raw 264.7 cells: the role of tumor necrosis factor-1. Cancer Res 2000; 60: 6326–6331.
29. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343–1352.
30. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transport gene transcription. Science 1987; 235: 1495–1498.
31. Haber RS, Rathan A, Weiser KR, Pritsker A, Irzkowitz SH, Bodian C, et al. GLUT1 Glucose transporter expression in colorectal carcinoma. A marker for poor prognosis. Cancer 1998; 83: 34–40.
32. Le Roith D. Tumor-induced hypoglycemia. N Engl J Med 1999; 341: 757–758.
33. Bruce WR, Wolever TM, Giacca A. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer 2000; 37: 19–26.
34. Chu SW, Hwang SJ, Luo JC. Hepatocellular carcinoma. Manifestation of hypercholesterolaemia, hypoglycaemia, erythrocytosis and hypercalcaemia in patients with hepatocellular carcinoma: report of two cases. J Gastroenterol Hepatol 1999; 14: 807–810.
35. Johnson JB. Paraneoplastic syndromes. In: Harrison's principles of internal medicine, 14th edn. New York: McGraw-Hill; 1998. pp. 618–622.